CANbridge Pharmaceuticals Inc. (01228) Announces November 2025 Monthly Return, Share Capital Remains Unchanged

Bulletin Express

Dec 04, 2025

CANbridge Pharmaceuticals Inc. (01228) released its Monthly Return for November 2025, reporting no changes to overall share capital. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000.

The total number of issued shares stands unchanged at 510,826,484. During the month, 60,000 share options under the Post-IPO Share Option Scheme lapsed, leaving 8,548,750 options outstanding. No new shares were issued, and no treasury shares were transferred or cancelled. The company received no proceeds from the exercise of share options.

Under the Pre-IPO Equity Incentive Plan, 21,858,960 shares remain available for future issuance, while the Post-IPO RSU Scheme shows no shares available. The confirmation was submitted by Chairman, Dr. James Qun Xue, on December 4, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1182755773"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182755773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182755773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182755773","market":"hk","top_or_hot":-1,"title":"CANbridge Pharmaceuticals Inc. (01228) Announces November 2025 Monthly Return, Share Capital Remains Unchanged","media":"Bulletin Express","content":"<p>CANbridge Pharmaceuticals Inc. (01228) released its Monthly Return for November 2025, reporting no changes to overall share capital. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000.</p>\n<p>The total number of issued shares stands unchanged at 510,826,484. During the month, 60,000 share options under the Post-IPO Share Option Scheme lapsed, leaving 8,548,750 options outstanding. No new shares were issued, and no treasury shares were transferred or cancelled. The company received no proceeds from the exercise of share options.</p>\n<p>Under the Pre-IPO Equity Incentive Plan, 21,858,960 shares remain available for future issuance, while the Post-IPO RSU Scheme shows no shares available. The confirmation was submitted by Chairman, Dr. James Qun Xue, on December 4, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANbridge Pharmaceuticals Inc. (01228) Announces November 2025 Monthly Return, Share Capital Remains Unchanged</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANbridge Pharmaceuticals Inc. (01228) Announces November 2025 Monthly Return, Share Capital Remains Unchanged\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-04 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANbridge Pharmaceuticals Inc. (01228) released its Monthly Return for November 2025, reporting no changes to overall share capital. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000.</p>\n<p>The total number of issued shares stands unchanged at 510,826,484. During the month, 60,000 share options under the Post-IPO Share Option Scheme lapsed, leaving 8,548,750 options outstanding. No new shares were issued, and no treasury shares were transferred or cancelled. The company received no proceeds from the exercise of share options.</p>\n<p>Under the Pre-IPO Equity Incentive Plan, 21,858,960 shares remain available for future issuance, while the Post-IPO RSU Scheme shows no shares available. The confirmation was submitted by Chairman, Dr. James Qun Xue, on December 4, 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01228","symbol_name":"北海康成-B","start_time":0,"source_url":"","article_id":"1182755773","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182755773","pubTimestamp":1764841583,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CANbridge Pharmaceuticals Inc. (01228) released its Monthly Return for November 2025, reporting no changes to overall share capital. The authorized share capital remains at 5,000,000,000 ordinary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01228":"北海康成-B"},"translate_title":"CANbridge Pharmaceuticals Inc.(01228)公布2025年11月月报表，股本维持不变","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01228":1},"content_text":"CANbridge Pharmaceuticals Inc. (01228) released its Monthly Return for November 2025, reporting no changes to overall share capital. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000.\nThe total number of issued shares stands unchanged at 510,826,484. During the month, 60,000 share options under the Post-IPO Share Option Scheme lapsed, leaving 8,548,750 options outstanding. No new shares were issued, and no treasury shares were transferred or cancelled. The company received no proceeds from the exercise of share options.\nUnder the Pre-IPO Equity Incentive Plan, 21,858,960 shares remain available for future issuance, while the Post-IPO RSU Scheme shows no shares available. The confirmation was submitted by Chairman, Dr. James Qun Xue, on December 4, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}